RANZCP homepage
Clinical guidelines & publications library
Guidance and publications produced by the RANZCP. Filter by type, topic, date or category.
-
Guidance for authorised prescribers of MDMA and psilocybin
Psychedelics
To provide guidance to psychiatrists following the Therapeutic Goods Administration’s (TGA) May 2026 recommendations regarding access to 3,4-methylenedioxy-methamphetamine (MDMA) and psilocybin for the purpose of psychedelic-assisted therapy (PAT). PDF Clinical guideline
Clinical guideline- Last updated: May 2026
-
Psychedelic training framework for psychiatrists
Psychedelics
Information for psychiatrists about psychedelic-assisted therapy with MDMA and psilocybin.
Clinical guideline- Last updated: Jun 2025
- Published in Australia
-
Appropriate use of MDMA-assisted psychotherapy for PTSD
PTSD, Psychedelics
This resource is regarded as a RANZCP Best Practice Resource (BPR) Endorsed Clinical Guideline for the appropriate use of Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder. URL Clinical guideline
Clinical guideline- Last updated: Mar 2025
- Published in Australia
- Best Practice Resource: Endorsed Clinical Guideline
-
Therapeutic use of MDMA for PTSD and psilocybin for treatment resistant depression
Ethics, Psychedelics, Professionalism
Information for psychiatrists about psychedelic-assisted therapy with MDMA and psilocybin. PDF Clinical guideline
Clinical guideline- Last updated: Jun 2023
- Published in Australia
-
Therapeutic use of psychedelic substances
Psychedelics
Information for psychiatrists about the potential utility of psychedelic substances to assist in treating mental illness. PDF Clinical guideline
Clinical guideline- Last updated: Jun 2023
- Published in Australia
-
Public consultation on interim decisions to amend the Poisons Standard
Psychedelics
RANZCP Submission providing input on the interim decision to amend Poisons Standards.
Submission- Last updated: Mar 2023
- Published in Australia
